危重新生儿及婴儿的基因组分析:高产出表型与小拷贝数变异的贡献
这项在日本17家三级中心开展的前瞻性研究,对85例6月龄以下危重新生儿及婴儿行医学外显子、全外显子或全基因组测序,48%获阳性诊断;代谢、肾脏、神经表型诊断产出较高,全基因组测序检出的小拷贝数变异占全部患者的5%,且49%获分子诊断者临床管理发生改变。
要点
- 危重新生儿及婴儿基因组分析总诊断产出为48%(41/85)。
- 代谢表型诊断产出最高(67%,4/6),其次为肾脏(60%,3/5)和神经表型(58%,14/24)。
- 全基因组测序检出的小拷贝数变异占全部患者的5%,且49%获分子诊断者临床管理改变。
核心结论
- 对危重新生儿及婴儿行基因组分析,在代谢、肾脏和神经表型中诊断产出较高。
- 全基因组测序检出的小拷贝数变异对全部患者的分子诊断贡献为5%。
- 获得的分子诊断对临床管理有显著影响。
研究设计与样本
- 研究为日本17家三级中心开展的前瞻性研究,时间范围为2019年4月至2021年3月。
- 招募对象为新生儿重症监护病房及门诊中6月龄以下的危重新生儿和婴儿。
- 患者首先接受医学外显子、全外显子或全基因组测序,医学外显子或全外显子阴性者后续行全基因组测序。
- 通过联系初级保健医生评估分子诊断对临床管理的影响。
主要发现
- 85例患者中41例(48%)获得阳性结果。
- 按主要症状,代谢表型诊断产出最高(67%,4/6),其次为肾脏(60%,3/5)和神经表型(58%,14/24)。
- 其中4例患者通过全基因组测序检出致病性小拷贝数变异。
- 41例获分子诊断的患者中,20例(49%)临床管理发生改变。
临床怎么用
- 对6月龄以下危重新生儿及婴儿,尤其代谢、肾脏或神经表型者,可考虑基因组分析作为一线检测。
- 医学外显子或全外显子阴性时,后续全基因组测序有助于检出小拷贝数变异。
- 分子诊断结果可用于指导临床管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To delineate the diagnostic efficacy of medical exome, whole exome, and whole genome sequencing according to primary symptoms, the contribution of small copy number variations, and the impact of molecular diagnosis on clinical management. STUDY DESIGN: This was a prospective study of 17 tertiary care centers in Japan, conducted between April 2019 and March 2021. Critically ill neonates and infants less than 6 months of age were recruited in neonatal intensive care units and in outpatient clinics. The patients underwent medical exome, whole exome, or whole genome sequencing as the first tier of testing. Patients with negative results after medical exome or whole exome sequencing subsequently underwent whole genome sequencing. The impact of molecular diagnosis on clinical management was evaluated through contacting primary care physicians. RESULTS: Of the 85 patients, 41 (48%) had positive results. Based on the primary symptoms, patients with metabolic phenotypes had the highest diagnostic yield (67%, 4/6 patients), followed by renal (60%, 3/5 patients), and neurologic phenotypes (58%, 14/24 patients). Among them, 4 patients had pathogenic small copy number variations identified using whole genome sequencing. In the 41 patients with a molecular diagnosis, 20 (49%) had changes in clinical management. CONCLUSIONS: Genome analysis for critically ill neonates and infants had a high diagnostic yield for metabolic, renal, and neurologic phenotypes. Small copy number variations detected using whole genome sequencing contributed to the overall molecular diagnosis in 5% of all the patients. The resulting molecular diagnoses had a significant impact on clinical management.
引用
- Suzuki H, Nozaki M, Yoshihashi H, et al. Genome Analysis in Sick Neonates and Infants: High-yield Phenotypes and Contribution of Small Copy Number Variations. J Pediatr. 2022. PMID: 35131284. doi:10.1016/j.jpeds.2022.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。